Research Topics
Species | L ForetovaSummaryAffiliation: Masaryk Memorial Cancer Institute Country: Czech Republic Publications
| Collaborators
|
Detail Information
Publications
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech RepublicPetra Vasickova
Masaryk Memorial Cancer Institute, Brno, Czech Republic
BMC Med Genet 8:32. 2007..The purpose of this study was to determine the type and frequency of large genomic rearrangements in the BRCA1 gene in hereditary breast and ovarian cancer cases in the Czech Republic...- Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancerEva Machackova
Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
BMC Cancer 8:140. 2008..One thousand and ten unrelated high-risk probands with breast and/or ovarian cancer were analysed for the presence of a BRCA1 or BRCA2 gene mutation at the Masaryk Memorial Cancer Institute (Czech Republic) during 1999-2006... - Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experienceL Foretova
Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
Klin Onkol 23:388-400. 2010..However, in some patients the testing is not recommended and other family members are dying because of the late diagnosis of hereditary syndrome. Greater awareness of the importance of genetic testing in oncology is needed... - Genetic and preventive services for hereditary breast and ovarian cancer in the czech republicLenka Foretova
Masaryk Memorial Cancer Institute Brno
Hered Cancer Clin Pract 4:3-6. 2006..The quality of preventive care in different hospitals is currently being investigated... - BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech RepublicLenka Foretova
Department of Cancer Epidemiology and Genetics, and Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53 Czech Republic
Hum Mutat 23:397-8. 2004..2%) of 32 women with sporadic early-onset unilateral breast cancer. No mutation was detected in 5 cases of sporadic early-onset unilateral ovarian cancer... - [Limitations of genetic testing in oncology]L Foretova
Oddelení epidemiologie a genetiky nádorů, Masarykův onkologický ú, Brno
Klin Onkol 22:S65-8. 2009..In some variants it is not clear yet whether they are just insignificant polymorphisms or pathogenic mutations. The interpretation of test results in the context of the whole family history is important... - Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech RepublicE Machackova
Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic
Hum Mutat 18:545. 2001.... - A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer familiesE Machackova
Cas Lek Cesk 139:635-7. 2000..About 5-10% of breast and ovarian cancer can be of hereditary origin. Germline mutations in BRCA1 or BRCA2 and probably other yet unknown genes may cause predisposition to these cancers... - [Male breast cancer--our experience]L Fiala
Masarykův onkologický ústav Brno, Oddelení Chirurgické Onkologie
Rozhl Chir 89:612-8. 2010..2% of all cancers. The ratio of female to male breast cancer is approximately 100:1. In this study, we review our experience with diagnosis, surgical treatment, and overall management of patients with MBC... - Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2Kathleen Claes
Center for Medical Genetics, Ghent University Hospital, Belgium
Genes Chromosomes Cancer 37:314-20. 2003..Furthermore, our study is important for a better understanding of splicing mechanisms and revealed new patterns of alternative splicing in BRCA1 and BRCA2... - AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 studyFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 16:1416-21. 2007..In summary, the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers... - The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech RepublicZdenek Kleibl
Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U nemocnice 5, Prague, 12853, Czech Republic
Breast Cancer Res Treat 90:165-7. 2005..1100delC mutation varies among different populations. Based on our results, genotyping of CHEK2 c.1100delC mutation in clinical settings in the Czech Republic could not be recommended... - Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancerTom Walsh
Department of Medicine and Genome Sciences, University of Washington, Seattle, WA 98195-7720, USA
JAMA 295:1379-88. 2006..Effective methods for identifying these mutations should be made available to women at high risk... - Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genesFederica Gemignani
Genetics, Department of Biology, University of Pisa, Pisa, Italy
Carcinogenesis 28:1287-93. 2007..Finally, extensive EPHX1 metabolizers showed an increased risk as compared with the poor metabolizers... - A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumorsMarie Trkova
Institute of Biology and Medical Genetics, Second Medical School, Charles University, Prague, Czech Republic
Cancer Genet Cytogenet 145:60-4. 2003..The product of the normal allele can potentially be inactivated by a variety of other mechanisms or, as suggested by the analysis, many of these tumors may even preserve the activity of the wild-type p53 protein... - Inherited predisposition of lung cancer: a hierarchical modeling approach to DNA repair and cell cycle control pathwaysRayjean J Hung
IARC, 150 cours Albert Thomas, F 69372 Lyon Cedex 08, France
Cancer Epidemiol Biomarkers Prev 16:2736-44. 2007..In particular, further investigation of OGG1, MGMT, and CHEK2 focusing on the genetic regions where the present markers are located or the haplotype blocks tightly linked with these markers might be warranted... - A rare tumor and an ethical dilemma in a family with a germline TP53 mutationKamila Prochazkova
Department of Biology and Medical Genetics, Charles University 2nd Medical School and University Hospital Motol, Vuvalu 84, 15006 Prague 5, Czech Republic
Cancer Genet Cytogenet 180:65-9. 2008..The case illustrates ethical problems associated with early predisposition testing in LFS, and the lack of consensus on this issue in the literature... - Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymphRomain Casey
Registre des Hémopathies Malignes de Côte d Or, EA INSERM InVs 4T0003C, faculté de médecine de Dijon, 7 Boulevard Jeanne d Arc, 21 000 Dijon, France
Eur J Cancer 42:2570-6. 2006..Our study suggests familial aggregation of CLL with a family history of haematological cancer and of HL with a family history of lymphoma. The transmission pattern suggests a dominant model of heredity... - Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph)Sophia S Wang
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Bethesda, MD 20892, USA
Blood 109:3479-88. 2007..0; 95% CI = 1.6-5.6). The pattern of NHL heritability appeared to be uniform across NHL subtypes, but risk patterns differed by specific hematopoietic malignancies and the sex of the relative, revealing critical clues to disease etiology... - Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controlsSilvia de Sanjose
Servei d Epidemiologia and Registre del Cancer, IDIBELL, Institut Catala d Oncologia, Gran Via Km 2 7, 08907 L Hospitalet, Barcelona, Spain
Int J Cancer 121:1806-12. 2007..Ab_EBV is a useful tool to explore EBV imbalances preceding or paralleling possible EBV associated oncogenic events...